NorthWest Biotherapeutics Inc (NWBO)

[dr_lowenstein]

offering a crossover trial design which was by request of FDA

no proof of that, and even if the FDA suggested they think about crossover they certainly did not expect what nwbo actually did .

Due to the cross-over study design, nearly 90% of the patients in this study received DCVax-L, making an interpretation of the survival outcome challenging.